Squarepoint Ops LLC Has $12.91 Million Stock Holdings in uniQure N.V. $QURE

Key Points

• Squarepoint Ops LLC cut its uniQure stake by 19% in the second quarter, selling 65,683 shares and retaining 280,300 shares valued at approximately $12.91 million. Institutional investors and hedge funds collectively own 78.83% of QURE.
• Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and a $65 price target. Fourteen analysts rate the stock Buy, compared with two Holds and one Sell.
• uniQure shares opened at $46, while the company reported a quarterly loss of $1.22 per share, missing estimates of $0.82, despite revenue of $5.84 million exceeding expectations.

Squarepoint Ops LLC lowered its stake in uniQure N.V. (NASDAQ:QURE - Free Report) by 19.0% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 280,300 shares of the biotechnology company's stock after selling 65,683 shares during the period. Squarepoint Ops LLC owned approximately 0.40% of uniQure worth $12,911,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Avoro Capital Advisors LLC boosted its stake in uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company's stock valued at $147,170,000 after purchasing an additional 1,705,556 shares during the period. State Street Corp lifted its holdings in shares of uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company's stock worth $77,319,000 after buying an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company's stock worth $70,226,000 after buying an additional 1,785,275 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of uniQure by 6,641.2% in the second quarter. California State Teachers Retirement System now owns 2,423,263 shares of the biotechnology company's stock valued at $111,615,000 after acquiring an additional 2,387,316 shares during the period. Finally, Orbimed Advisors LLC grew its stake in shares of uniQure by 189.7% in the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company's stock valued at $34,926,000 after acquiring an additional 1,398,749 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on QURE. Barclays lowered their price target on shares of uniQure from $65.00 to $60.00 and set an "overweight" rating on the stock in a research report on Thursday, July 30th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of uniQure in a report on Friday, June 26th. William Blair initiated coverage on shares of uniQure in a research report on Wednesday, September 2nd. They issued an "outperform" rating for the company. Wolfe Research upgraded uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 price target for the company in a research note on Wednesday, July 29th. Finally, Cantor Fitzgerald raised uniQure from a "neutral" rating to an "overweight" rating and set a $61.00 price target on the stock in a research report on Wednesday, June 17th. Fourteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, uniQure currently has a consensus rating of "Moderate Buy" and a consensus price target of $65.00.

uniQure Trading Up 0.7%

Shares of uniQure stock opened at $46.00 on Thursday. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The company has a market capitalization of $3.19 billion, a price-to-earnings ratio of -11.47 and a beta of 0.94. The firm's 50-day moving average price is $44.25 and its two-hundred day moving average price is $30.88.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The firm had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.45 million. During the same period last year, the business earned ($0.69) earnings per share. On average, analysts forecast that uniQure N.V. will post -3.82 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Walid Abi-Saab sold 30,000 shares of uniQure stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total value of $1,392,600.00. Following the transaction, the insider owned 148,235 shares in the company, valued at approximately $6,881,068.70. This trade represents a 16.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew Kapusta sold 21,082 shares of the business's stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $45.16, for a total value of $952,063.12. Following the transaction, the chief executive officer directly owned 519,227 shares of the company's stock, valued at $23,448,291.32. This trade represents a 3.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 347,412 shares of company stock worth $15,712,415. 4.65% of the stock is owned by company insiders.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure N.V. (NASDAQ:QURE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.